tiprankstipranks
Trending News
More News >
Adaptimmune Therapeutics Plc. (ADAPY)
:ADAPY
US Market
Advertisement

Adaptimmune Therapeutics (ADAPY) Stock Forecast & Price Target

Compare
1,279 Followers
See the Price Targets and Ratings of:

ADAPY Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Adaptimmune
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ADAPY Stock 12 Month Forecast

There Are No Analyst Ratings for ADAPY In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

ADAPY Financial Forecast

ADAPY Earnings Forecast

Next quarter’s earnings estimate for ADAPY is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.02. ADAPY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ADAPY has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ADAPY is -$0.12 with a range of -$0.12 to -$0.12. The previous quarter’s EPS was -$0.02. ADAPY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ADAPY has Preformed in-line its overall industry.

ADAPY Sales Forecast

Next quarter’s sales forecast for ADAPY is $4.85M with a range of $0.00 to $9.70M. The previous quarter’s sales results were $13.84M. ADAPY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ADAPY has Preformed in-line its overall industry.
Next quarter’s sales forecast for ADAPY is $4.85M with a range of $0.00 to $9.70M. The previous quarter’s sales results were $13.84M. ADAPY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ADAPY has Preformed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on ADAPY
Barclays
Barclays
$0.46
Sell
666.67%
Upside
Reiterated
08/14/25
Adaptimmune Therapeutics (ADAP) Gets a Sell from Barclays
Leerink Partners Analyst forecast on ADAPY
Leerink Partners
Leerink Partners
$0.11$0.09
Hold
50.00%
Upside
Reiterated
08/13/25
Hold Rating Maintained for Adaptimmune Therapeutics Amid Revenue Growth and Strategic Uncertainties
Guggenheim Analyst forecast on ADAPY
Guggenheim
Guggenheim
Hold
Downgraded
07/29/25
Adaptimmune downgraded to Neutral from Buy at GuggenheimAdaptimmune downgraded to Neutral from Buy at Guggenheim
H.C. Wainwright Analyst forecast on ADAPY
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
07/29/25
H.C. Wainwright downgrades Adaptimmune Therapeutics (ADAP) to a Hold
Wells Fargo Analyst forecast on ADAPY
Wells Fargo
Wells Fargo
$1.5$1
Hold
1566.67%
Upside
Reiterated
05/14/25
Wall Street Analysts Are Neutral on Top Healthcare Picks
Scotiabank Analyst forecast on ADAPY
Scotiabank
Scotiabank
$1.4
Buy
2233.33%
Upside
Reiterated
05/14/25
Scotiabank Keeps Their Buy Rating on Adaptimmune Therapeutics (ADAP)
TD Cowen Analyst forecast on ADAPY
TD Cowen
TD Cowen
Buy
Reiterated
11/14/24
Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Barclays Analyst forecast on ADAPY
Barclays
Barclays
$0.46
Sell
666.67%
Upside
Reiterated
08/14/25
Adaptimmune Therapeutics (ADAP) Gets a Sell from Barclays
Leerink Partners Analyst forecast on ADAPY
Leerink Partners
Leerink Partners
$0.11$0.09
Hold
50.00%
Upside
Reiterated
08/13/25
Hold Rating Maintained for Adaptimmune Therapeutics Amid Revenue Growth and Strategic Uncertainties
Guggenheim Analyst forecast on ADAPY
Guggenheim
Guggenheim
Hold
Downgraded
07/29/25
Adaptimmune downgraded to Neutral from Buy at GuggenheimAdaptimmune downgraded to Neutral from Buy at Guggenheim
H.C. Wainwright Analyst forecast on ADAPY
H.C. Wainwright
H.C. Wainwright
Hold
Downgraded
07/29/25
H.C. Wainwright downgrades Adaptimmune Therapeutics (ADAP) to a Hold
Wells Fargo Analyst forecast on ADAPY
Wells Fargo
Wells Fargo
$1.5$1
Hold
1566.67%
Upside
Reiterated
05/14/25
Wall Street Analysts Are Neutral on Top Healthcare Picks
Scotiabank Analyst forecast on ADAPY
Scotiabank
Scotiabank
$1.4
Buy
2233.33%
Upside
Reiterated
05/14/25
Scotiabank Keeps Their Buy Rating on Adaptimmune Therapeutics (ADAP)
TD Cowen Analyst forecast on ADAPY
TD Cowen
TD Cowen
Buy
Reiterated
11/14/24
Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Adaptimmune Therapeutics

1 Month
xxx
Success Rate
0/0 ratings generated profit
Average Return
-
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in - of your transactions generating a profit, with an average return of - per trade.
3 Months
xxx
Success Rate
0/0 ratings generated profit
Average Return
-
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in - of your transactions generating a profit, with an average return of - per trade.
1 Year
Peter LawsonBarclays
Success Rate
9/12 ratings generated profit
Average Return
+21.79%
reiterated a sell rating 3 months ago
Copying Peter Lawson's trades and holding each position for 1 Year would result in - of your transactions generating a profit, with an average return of +21.79% per trade.
2 Years
xxx
Success Rate
0/0 ratings generated profit
Average Return
-
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in - of your transactions generating a profit, with an average return of - per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ADAPY Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
3
2
0
0
0
Buy
0
0
0
0
0
Hold
13
20
20
19
13
Sell
1
1
1
1
1
Strong Sell
0
0
4
6
6
total
17
23
25
26
20
In the current month, ADAPY has received 0 Buy Ratings, 13 Hold Ratings, and 7 Sell Ratings. ADAPY average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

ADAPY Stock Forecast FAQ

What is ADAPY’s average 12-month price target, according to analysts?
Currently, no data Available
What is ADAPY’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for ADAPY, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is ADAPY a Buy, Sell or Hold?
      Currently, no data Available
      What is Adaptimmune Therapeutics Plc.’s price target?
      Currently, no data Available
      What do analysts say about Adaptimmune Therapeutics Plc.?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of ADAPY?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis